Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer

Komazaki, Yoshitoshi; Sakashita, Hiroyuki; Furuiye, Masashi; Fujie, Toshihide; Tamaoka, Meiyo; Sumi, Yuki; Miyazaki, Yasunari; Kojima, Katsuo; Jin, Yasuto; Inase, Naohiko

doi:10.1159/000351101

Cited by 6 publications

(6 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In the present study, completion rate was 78.9%, which was comparable to that of the two previous trials. 13,14 In this study, the rate of grade 3 or 4 hematological AEs were low, and grade 3 thrombocytopenia were seen about 15%, which was comparable to the numbers in previous studies. 13,14 Although carboplatin-based regimens are generally less emetogenic than cisplatin-based ones, higher dose of carboplatin (AUC ≥ 4) was classified as highly emetogenic chemotherapy.…”

Section: Discussionsupporting

confidence: 89%

“…13,14 In this study, the rate of grade 3 or 4 hematological AEs were low, and grade 3 thrombocytopenia were seen about 15%, which was comparable to the numbers in previous studies. 13,14 Although carboplatin-based regimens are generally less emetogenic than cisplatin-based ones, higher dose of carboplatin (AUC ≥ 4) was classified as highly emetogenic chemotherapy. 19 We observed that the incidence of grade three non-hematological AEs was low.…”

Section: Discussionsupporting

confidence: 89%

“…Komazaki and colleagues reported the feasibility and compliance of adjuvant chemotherapy of S-1 (80 mg/m 2 ) plus carboplatin (AUC 6) for patients with completely resected stage IB-IIIA NSCLC. 13 The completion rate of three cycles was 82.4%, and they concluded adjuvant chemotherapy with S-1 plus carboplatin was well tolerated. 13 In another study, Okumura and colleagues reported a multicenter prospective study that evaluated the feasibility of adjuvant chemotherapy with four cycles of S-1 (80 mg/m 2 /day for two weeks) plus carboplatin (AUC 5) followed by single-agent S-1 maintenance.…”

Section: Discussionmentioning

confidence: 95%

“…13 The completion rate of three cycles was 82.4%, and they concluded adjuvant chemotherapy with S-1 plus carboplatin was well tolerated. 13 In another study, Okumura and colleagues reported a multicenter prospective study that evaluated the feasibility of adjuvant chemotherapy with four cycles of S-1 (80 mg/m 2 /day for two weeks) plus carboplatin (AUC 5) followed by single-agent S-1 maintenance. 14 The completion rates of four cycles of S-1 plus carboplatin and the following S-1 maintenance therapy were 89.7% and 63.2%, respectively.…”

Section: Discussionmentioning

confidence: 95%

“…No PE event has been described in previous studies on S-1 based chemotherapy for NSCLC. [13][14][15][16][17] Therefore, the causal relationship between chemotherapy and PE remains unclear. Both patients in our study who developed PE were female, which has been reported to be an independent predictor for VTE.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background: Adjuvant chemotherapy with platinum-based regimens for completely resected early-stage non-small cell lung cancer (NSCLC) provides overall survival benefit in several clinical trials. Objectives: We conducted this prospective study to evaluate the efficacy and safety of adjuvant chemotherapy with carboplatin and S-1 for patients with completely resected stage II to IIIA NSCLC. Methods: Patients with completely resected stage IIA to IIIA NSCLC were treated with four cycles of carboplatin with area under the concentration time curve of 5 mg/mL/min on day 1 plus S-1 at 80-120 mg/bodyweight per day for two weeks, followed by one-week rest as adjuvant chemotherapy. The primary endpoint was the completion rate of three cycles of the treatment. The secondary endpoints were safety and two-year survival rate. Results: A total of 19 patients were enrolled, until the study was terminated prematurely because of fatal pulmonary embolism in two patients. The median number of treatment cycles was three (range: 1-4). The completion rate of three cycles was 78.9% (95% confidence interval [CI]: 56.6-91.4%). Two-year diseasefree survival rate was 57.8%. Grade 3 or 4 hematological toxicities included neutropenia (26.2%), anemia (5.2%), and thrombocytopenia (15.7%). Grade 3 or 4 nonhematological toxicities were anorexia (10.5%) and nausea (10.5%). Febrile neutropenia developed in 5.2%. In two patients (10.5%), grade five pulmonary embolism was observed, and the causal relationship with treatment could not be denied.Conclusions: Carboplatin and oral S-1 had modest survival benefit, but this regimen was not tolerable in an adjuvant setting because fatal pulmonary embolism occurred in two patients. Key points• Carboplatin and oral S-1 had modest survival benefit but this regimen was not tolerable. • Fatal pulmonary embolism occurred in this regimen.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer

2018

View full text Add to dashboard Cite

We investigated the efficacy of concurrent radiotherapy plus S-1 (CRS) for treating unresectable stage III advanced non-small-cell lung cancer (ANSCLC).Seventy five ANSCLC patients were included in this retrospective study. Of those, 40 patients were assigned to an intervention group, and received S-1 (orally at 40 mg/m) twice daily for 14 consecutive days. Then, concurrent radiotherapy was administered in 2 Gy fractions, 5 times weekly for a total dose of 60 Gy. The other 35 patients were assigned to a control group, and underwent concurrent radiotherapy (the same as the intervention group) and cisplatin (60 mg/m on day 1 (CRC). The outcome measurements included overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and toxicity.The 3-year ORR was 60.7% and 43.9% for intervention group and control group, respectively (P = .031). The median OS was 34.1 months and 25.3 months in the intervention and control groups, respectively (P = .041). The median PFS was 31.5 months for intervention group, while it was 22.4 months for control group (P = .048). No significant difference in toxicity was found between the 2 groups.The results demonstrated that the efficacy of CRS was superior to the CRC in ANSCLC patients with similar toxicity.

show abstract

Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer

Han

Wei

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) is the most common lung cancer. Numerous clinical studies have reported that the combination of carboplatin and S-1 (CS) can be used to treat NSCLC effectively. However, no systematic review has been conducted to assess its efficacy and safety for NSCLC. This systematic review aims to evaluate the efficacy and safety of CS for treatment of patients with NSCLC. Methods: This study will retrieve the following electronic databases from inception to the February 1, 2019: Cochrane Library, EMBASE, MEDILINE, CINAHL, AMED, and 4 Chinese databases without any language limitations. This systematic review will include randomized controlled trials (RCTs) and case-control studies for assessing the efficacy and safety of CS for the treatment of NSCLC. Cochrane risk of bias will be used as methodological quality assessment for each qualified study. The RevMan V.5.3 software will be utilized to synthesize the data and conduct the meta-analysis if it is allowed. The data will be pooled by using the random-effects model or fixed-effects model. Results: The primary outcome is overall response rate. The secondary outcomes are overall survival, progression-free survival, the disease control rate, and any adverse events. Conclusion: It will provide latest evidence to determine the efficacy and safety of CS for treatment of patients with NSCLC. Ethics and dissemination: No research ethic approval is needed in this study because this study will not analyze individual patient data. The results are expected to disseminate through peer-reviewed journals. Systematic review registration: PROSPERO CRD42019124860.

show abstract

Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer

Cited by 6 publications

References 59 publications

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer

A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer

Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer

Contact Info

Product

Resources

About